Literature DB >> 20723038

A perspective on modelling hepatitis C virus infection.

J Guedj1, L Rong, H Dahari, A S Perelson.   

Abstract

By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of interferon (IFN)-based antiviral therapy, crucial parameters of the in vivo viral kinetics have been estimated, such as the rate of production and clearance of free virus, and the rate of loss of infected cells. Furthermore, by suggesting mechanisms of action for IFN and ribavirin mathematical modelling has provided a means for evaluating and optimizing treatment strategies. Here, we review recent modelling developments for understanding complex viral kinetics patterns, such as triphasic HCV RNA declines and viral rebounds observed in patients treated with pegylated interferon and ribavirin. Moreover, we discuss new modelling approaches developed to interpret the viral kinetics observed in clinical trials with direct-acting antiviral agents, which induce a rapid decline of wild-type virus but also engender a higher risk for emergence of drug-resistant variants. Lastly, as in vitro systems have allowed a better characterization of the virus lifecycle, we discuss new modelling approaches that combine the intracellular and the extracellular viral dynamics.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20723038      PMCID: PMC3070361          DOI: 10.1111/j.1365-2893.2010.01348.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  66 in total

1.  Bayesian experimental design for nonlinear mixed-effects models with application to HIV dynamics.

Authors:  Cong Han; Kathryn Chaloner
Journal:  Biometrics       Date:  2004-03       Impact factor: 2.571

2.  Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors:  Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal:  Sci Transl Med       Date:  2010-05-05       Impact factor: 17.956

3.  In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Authors:  Chao Lin; Cynthia A Gates; B Govinda Rao; Debra L Brennan; John R Fulghum; Yu-Ping Luong; J Daniel Frantz; Kai Lin; Sue Ma; Yun-Yi Wei; Robert B Perni; Ann D Kwong
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

4.  A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

Authors:  Marcelo Silva; Jorge Poo; Frank Wagner; Mary Jackson; David Cutler; Michael Grace; Ronald Bordens; Connie Cullen; Joann Harvey; Mark Laughlin
Journal:  J Hepatol       Date:  2006-04-18       Impact factor: 25.083

5.  Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.

Authors:  Harel Dahari; Evaldo S Affonso de Araujo; Bart L Haagmans; Thomas J Layden; Scott J Cotler; Antonio A Barone; Avidan U Neumann
Journal:  J Hepatol       Date:  2010-05-27       Impact factor: 25.083

6.  ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS.

Authors:  Timothy C Reluga; Harel Dahari; Alan S Perelson
Journal:  SIAM J Appl Math       Date:  2009-01-14       Impact factor: 2.080

7.  A hepatitis C viral kinetic model that allows for time-varying drug effectiveness.

Authors:  Emi Shudo; Ruy M Ribeiro; Andrew H Talal; Alan S Perelson
Journal:  Antivir Ther       Date:  2008

8.  Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.

Authors:  Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

9.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

10.  Estimation of dynamical model parameters taking into account undetectable marker values.

Authors:  Rodolphe Thiébaut; Jérémie Guedj; Hélène Jacqmin-Gadda; Geneviève Chêne; Pascale Trimoulet; Didier Neau; Daniel Commenges
Journal:  BMC Med Res Methodol       Date:  2006-08-01       Impact factor: 4.615

View more
  41 in total

Review 1.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Locking out hepatitis C.

Authors:  Gisa Gerold; Charles M Rice
Journal:  Nat Med       Date:  2011-05       Impact factor: 53.440

3.  Drugs in development for viral hepatitis: care and caution.

Authors:  Paul J Pockros
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

4.  Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy.

Authors:  Jeremie Guedj; Harel Dahari; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-30       Impact factor: 11.205

5.  Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Authors:  Cédric Laouénan; Patrick Marcellin; Martine Lapalus; Feryel Khelifa-Mouri; Nathalie Boyer; Fabien Zoulim; Lawrence Serfaty; Jean-Pierre Bronowicki; Michelle Martinot-Peignoux; Olivier Lada; Tarik Asselah; Céline Dorival; Christophe Hézode; Fabrice Carrat; Florence Nicot; Gilles Peytavin; France Mentré; Jeremie Guedj
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

6.  Advanced Hepatitis C Virus Replication PDE Models within a Realistic Intracellular Geometric Environment.

Authors:  Markus M Knodel; Paul Targett-Adams; Alfio Grillo; Eva Herrmann; Gabriel Wittum
Journal:  Int J Environ Res Public Health       Date:  2019-02-12       Impact factor: 3.390

7.  Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Authors:  Jeremie Guedj; Harel Dahari; Ralf T Pohl; Peter Ferenci; Alan S Perelson
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

8.  3D Spatially Resolved Models of the Intracellular Dynamics of the Hepatitis C Genome Replication Cycle.

Authors:  Markus M Knodel; Sebastian Reiter; Paul Targett-Adams; Alfio Grillo; Eva Herrmann; Gabriel Wittum
Journal:  Viruses       Date:  2017-09-30       Impact factor: 5.048

Review 9.  Viral kinetic modeling: state of the art.

Authors:  Laetitia Canini; Alan S Perelson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-25       Impact factor: 2.745

10.  Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.

Authors:  Libin Rong; Alan S Perelson
Journal:  Math Biosci       Date:  2013-05-16       Impact factor: 2.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.